Аннотация:
Leflunomide is an antirheumatic drug with anti-inflammatory and antirheumatic properties, it is rapidly metabolized in the body to the active metabolite teriflunomide, which causes its pharmacological activity. At the usual 20-mg daily dosage of leflunomide, the expected teriflunomide plasma concentration is about 35 μg/ml. The pharmacokinetics of the drug is characterized by a large interindividual variability and a long half-life, which in combination with possible side effects creates the need to control the concentration of teriflunomide in the blood plasma. Teriflunomide may increase the risk of fetal death or teratogenic effects when administered to pregnant women. Teriflunomide plasma concentrations less than 0.02 μg/ml are preferred for patients anticipating pregnancy. In this study, a sensitive and high-performance method for analyzing teriflunomide in human blood plasma in a wide range of concentrations was developed and validated using a triple quadrupole liquid chromatograp
Moskaleva N. E. Natal`ya Evgenyevna 1971-
Mesonzhnik N. V. Natal`ya Vladimirovna 1983-
Kuznetsov R. M. Roman Mikhaylovich 1977-
Markin P. A. Pavel Aleksandrovich 1996-
Appolonova S. A. Svetlana Aleksandrovna 1973-
Москалева Н. Е. Наталья Евгеньевна 1971-
Месонжник Н. В. Наталья Владимировна 1983-
Кузнецов Р. М. Роман Михайлович 1977-
Маркин П. А. Павел Александрович 1996-
Апполонова С. А. Светлана Александровна 1973-
Determination of teriflunomide across a wide dynamic concentration range in human plasma by lc-ms/ms
Текст визуальный непосредственный
Periodico Tche Quimica
Vol.16, Issue32 P. 608-620
2019
Статья
Chromatography-mass spectrometry Pharmacokinetics Teriflunomide Therapeutic monitoring
Leflunomide is an antirheumatic drug with anti-inflammatory and antirheumatic properties, it is rapidly metabolized in the body to the active metabolite teriflunomide, which causes its pharmacological activity. At the usual 20-mg daily dosage of leflunomide, the expected teriflunomide plasma concentration is about 35 μg/ml. The pharmacokinetics of the drug is characterized by a large interindividual variability and a long half-life, which in combination with possible side effects creates the need to control the concentration of teriflunomide in the blood plasma. Teriflunomide may increase the risk of fetal death or teratogenic effects when administered to pregnant women. Teriflunomide plasma concentrations less than 0.02 μg/ml are preferred for patients anticipating pregnancy. In this study, a sensitive and high-performance method for analyzing teriflunomide in human blood plasma in a wide range of concentrations was developed and validated using a triple quadrupole liquid chromatograp